OBJECTIVES: In 2014, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancies Interest Group (ITMIG) launched a worldwide Tumor Node Metastasis (TNM) staging proposal for the next edition of thymic tumours. The objective of the current study was to evaluate the proposed new staging system specific to the thymic well-differentiated neuroendocrine carcinoma (TWDNC).
INTRODUCTION
Thymic well-differentiated neuroendocrine carcinoma (TWDNC) is extremely rare and only a few case series have been reported [1] . In 2014, the International Association for the Study of Lung Cancer (IASLC) and the International Thymic Malignancies Interest Group (ITMIG) jointly published a proposal for the forthcoming edition of the TNM classification of thymic epithelial neoplasms [2] . They recommended that this proposed staging system be also applicable to TWDNC for consistency, even though there were too few cases to analyse separately in their cohort of all thymic tumours.
To concur with the necessity of broader discussion before formal definition of stage classification, we reviewed our TWDNC patients in our hospital including no operation cases.
MATERIALS AND METHODS
A retrospective review of the medical charts of all consecutive patients with pathologically confirmed TWDNC patients who were treated from February 2003 to July 2014 was carried out at Shanghai Chest Hospital. Patient characteristics and outcomes were abstracted from medical records. Resection status was determined from operative notes and pathology reports. Indications for postoperative radiotherapy and chemotherapy were based on the surgeon's assessment of the risk of recurrence. Since July 2007, our clinical database of thymic tumours has been prospectively maintained. Institutional review board approval was granted for this retrospective review along with a waiver of patient consent.
All case staging followed the Masaoka-Koga system (Table 1) [3]  and IASLC/ITMIG proposed TNM system (Tables 2 and 3, respectively) [2]. Haematoxylin-eosin-stained sections from resected tissue blocks were available for review in all of the studied cases. According to the World Health Organization classification of 2004 [4] , typical carcinoid is a TWDNC morphology with ≤2 mitoses/2 mm 2 (10 high-power fields), small (<0.5 mm) areas of necrosis and mild cellular atypia. Atypical carcinoid is a tumour of moderately differentiated morphology with 3-10 mitoses/2 mm 2 ; more extensive areas of necrosis (1-2 cm) and moderate cellular atypia. Usual outpatient follow-up obtained primarily by chest computed tomography scan occurred at 3-month intervals for the first year, 6-month intervals for the subsequent year and yearly for the next years. Survival data not available in the medical record were obtained by contacting patients by telephone or mail. All outcome protocols were defined as the ITMIG 
Adapted from [2] .
suggested [5] . Recurrence was specified as local recurrence (anterior mediastinum), regional recurrence (intrathoracic, not contiguous with the thymus) and distant recurrence (intrapulmonary or extrathoracic). Combined recurrence was categorized as the more advanced one. Recurrence was diagnosed if proved by biopsy or by unequivocal evidence of tumour masses (newly appearing metastases or local recurrence) with a tendency to grow during further follow-up. Survival was defined as the interval between surgical intervention and the date of death or last follow-up. The last general follow-up of survivors was done at the end of October 2014. A total cohort of 61 patients were enrolled and 54 (89%) of them had complete follow-up data. Follow-up data were completed with a median of 36.7 months (range, 2-128 months). The χ 2 test was used to verify the association between categorical variables while continuous variables were evaluated with an unpaired t-test. Overall survival (OS) and disease-free survival (DFS) were estimated according to the Kaplan-Meier method. Difference in survival was evaluated with the log-rank test. The proposed clinical stage system was assessed by visual scrutiny of the curves and consideration of clinical relevance. Cox proportional hazards regression was used to calculate hazard ratios (HRs) between adjacent groups and to assess the prognostic value of the proposed stage groupings. Relevant variables found to be significant on univariate analysis (defined as a probability value of less than 0.15) were included in the multivariate analysis using the Cox proportional hazards model after backward stepwise Wald elimination. A probability value of less than 0.05 on multivariate analysis was considered significant. The prognostic ability of the two staging systems was verified by a multivariate analysis that considers other prognostic factors. All statistical analyses were performed using the SPSS software (version 20.0, Chicago, IL, USA).
RESULTS

Clinical features and survival
The demographic characteristics of the population are given in Table 4 . The presenting complaints were chest pain in 18 patients, shortness of breath in 13, cough in 4 and fever in 3. During the same period, 1195 thymomas and 305 thymic carcinoma pathologically confirmed patients were identified. Thymic carcinoids made up 4% of total thymic tumours. The OS rate at 5 years was 72%, and at 10 years it was 49%. The DFS rate was 41% at the 5-year mark. The median survival time was 88.4 ± 9.2 months and the median time of postoperative recurrence occurred at 60.0 ± 20.1 months after initial surgery. At the end of the study, 30 patients (56%) were alive with no evidence of disease progression, 13 were alive with the disease (24%) and 10 died of the disease (19%). One patient (2%) died from disease-unrelated causes postoperatively.
Validity evaluation of suggested changes to the proposed clinical stage system
The significant predictors of OS and DFS calculated by univariate and multivariate analysis are listed in Tables 5 and 6 , respectively. Neither the Masaoka-Koga staging system nor the proposed TNM system showed ordered appropriateness visually in survival curves (Fig. 1 ) and the prognostic demarcation between stages was poor on both OS and DFS ( Table 7) .
The proposed TNM staging system demonstrated failure on predicting both OS (HR = 1.109, P = 0.78) and DFS (HR = 1.147, P = 0.72) after controlling for potential confounders. The traditional Masaoka-Koga staging system predicts survival neither on OS (HR = 1.383, P = 0.61) nor DFS (HR = 1.040, P = 0.96).
DISCUSSION
The objective of this study was to validate the proposed IASLC/ ITMIG staging revisions in TWDNC patients. The principal finding is that neither the proposed TNM staging system nor the traditional Masaoka-Koga system predict clinical course in TWDNC patients.
Thymic neuroendocrine tumours are rare and studies to define evidence-based clinical staging system are limited. Owing to their diverse biological aggressiveness, we only focused on the TWDNC (typical carcinoids and atypical carcinoids) in our series, excluding the more distinct subset of small-cell carcinoma and large-cell neuroendocrine carcinoma. Before the published proposed TNM staging system by IASLC/ITMIG, there was no official staging system specific to the TWDNC. Many scholars subjectively adopted the Masaoka-Koga system originating from thymoma in clinical practice. The rationale of this study is that a solid stage system should be subjected to an intense validation process before being officially published and widely accepted.
The last recommended staging system of thymic tumours by ITMIG was the Masaoka-Koga system, based on the clinical data of 76 patients in 1994 [3] and revised from Masaoka four-stage system ( published in 1981, based on 93 thymoma patients) [6] . This staging system was not clinically validated in a large series specific to TWDNC. Filosso and associates confirmed that Masaoka stage failed to be an independent variable on predicting OS in 205 patients with thymic neuroendocrine tumours (P = 0.82) [7] . In our study, the OS curves based on the proposed system did not separate well as anticipated (P = 0.78), similarly to the Masaoka-Koga system (P = 0.61), and the separation of DFS curves was poor in both staging systems (P = 0.91 and P = 0.26, respectively). They were also not prognostically distinct when compared in a pairwise fashion by Cox regression analysis. The poor performance of prognostic discrimination of proposed WHO staging system in survival curves was observed, challenging the appropriateness of clinical acceptance. There were only 39% patients (24/61) that had lymph node retrieval for pathological evaluation. Because 79% of the patients (19/24) presented with lymphogenous metastases, we thought that a systematic removal of both N1 and N2 nodes-a minimum number of 10 dissected nodes-was logical during curative-intent resection as recommended by ITMIG [8] .
Our results should be interpreted with caution because the number of patients available for these subset analyses is relatively small with resultant hampering of robust analysis. In addition, our study suffered the retrospective study design and experience of a single centre. An international classification system must be reproducible in the diverse setting in which it is applied [9] . In our 61 patients, 5% (3/61) were managed non-surgically, thus making this finding more generalizable. In addition, the prognostic ability of the staging system was verified by a multivariate analysis that considers other prognostic factors, i.e. sex, age, completeness of resection, yielding comparatively statistically valid analyses.
In conclusion, the IASLC/ITMIG suggested that the TNM and Masaoka-Koga staging systems fail to predict the clinical course of TWDNC patients. Collaborative effort is needed in the future staging validation as ITMIG recommended.
